MiMedx Group ( (MDXG) ) has shared an update.
MiMedx Group announced its financial results for the fourth quarter and full year 2024, reporting a 7% increase in net sales for the quarter and 9% for the year. Despite challenges with Medicare reimbursement and commercial disruptions, the company achieved a net income of $7 million for the quarter and $42 million for the year. The CEO expressed confidence in the company’s growth prospects, highlighting plans to expand its wound and surgical businesses and adapt to market changes. The company also reported an increase in cash and cash equivalents, ending the year with $104 million.
More about MiMedx Group
MiMedx Group, Inc. operates in the healthcare industry, focusing on the development and commercialization of regenerative and therapeutic biologics. The company primarily offers products related to wound care and surgical applications, with an emphasis on innovative solutions and clinical evidence to support patient outcomes.
YTD Price Performance: -14.22%
Average Trading Volume: 631,858
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.17B
See more data about MDXG stock on TipRanks’ Stock Analysis page.